Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.54 EUR | +2.08% | +1.31% | -93.37% |
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 14.08M 15.2M |
---|---|---|---|---|---|
Net income 2023 * | -23M -24.83M | Net income 2024 * | -18M -19.43M | EV / Sales 2023 * | - |
Net cash position 2023 * | 24.1M 26.02M | Net cash position 2024 * | 19.55M 21.11M | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.58
x | P/E ratio 2024 * |
-0.75
x | Employees | 15 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.82% |
Latest transcript on Vivoryon Therapeutics N.V.
1 day | +2.08% | ||
1 week | +1.31% | ||
Current month | -93.65% | ||
1 month | -93.81% | ||
3 months | -93.25% | ||
6 months | -95.21% | ||
Current year | -93.37% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 18-08-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 74 | 06-12-31 | |
Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.54 | +2.08% | 157,960 |
24-03-27 | 0.529 | -2.04% | 226,661 |
24-03-26 | 0.54 | -1.46% | 137,146 |
24-03-25 | 0.548 | +0.55% | 78,963 |
24-03-22 | 0.545 | +2.25% | 73,077 |
Real-time Euronext Amsterdam, March 28, 2024 at 12:35 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-93.37% | 15.2M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
-8.77% | 11.06B |